PricingLoginNewsroom
Vol. II — No. 184Remarkable People · Exceptional CompaniesToday's Edition

astrocytoma

(2)
AllCompaniesPeopleStoriesProducts
Legend
Jason Levin Stayed With the Bet Long Enough for the Science to Change
Founder · Operator · Executive

Jason Levin Stayed With the Bet Long Enough for the Science to Change

For more than a decade, the Orbus co-founder helped carry one drug through financing, patents and a 343-patient trial. Then a new tumor classification changed the question - and the company’s next chapter.

jason-levin · orbus-therapeuticsRead →
Company
Orbus Bet $71 Million on One Brain-Cancer Trial - Then the Definition of the Disease Changed
Health

Orbus Bet $71 Million on One Brain-Cancer Trial - Then the Definition of the Disease Changed

A tiny Palo Alto biotech took an old molecule into a global Phase 3 trial. The broad result failed, but a new molecular map of brain cancer revealed where the drug may actually work - and offered a playbook for anyone building in a market whose definitions move mid-experiment.

orbus-therapeutics · biotechnologyRead →